AntiTNF-α agents in the treatment of inflammation

Bibliography

• AGGARWAL BB, NATARAJAN K: Tumor necrosis factors:developments during the last decade. Europ. Cytokine Network (1996) 7(2):93–124.
   PubMed Web of Science ®Google Scholar
• PESCHON JJ, TORRANCE DS, STOCKING KL et al.: TNFreceptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol (1998) 160:943–952.
   PubMed Web of Science ®Google Scholar
• GEORGOPOUOS S, PLOWS D, KOLLIAS G: Transmem-brane TNF is sufficient to induce localized tissue toxic-ity and chronic inflammatory arthrittis in transgenic mice. J. Inflamm. (1996) 46:86.
   PubMedGoogle Scholar
• BUTLER DM, MALFAIT A-M, MASON LJ et al.: BDA/1 mice expressing the humane TNF-a transgene develop a se-vere, erosive arthritis. Characterization of the cyto-kine cascade and cellular composition. J. Immun. (1997) 159:2867–2876.
   Google Scholar
• SEKUT L, CONNOLLY KM: Pathophysiology and regula-tion of TNF-a in inflammation. Drug News Perspect (1996) 9(5):261–269.
   Web of Science ®Google Scholar
• EIGLER A, SINHA B, HARTMANN G, ENDRES S: Taming TNF: strategies to restrain this proinflammatory cyto-kine. Immun. Today (1997).
   Google Scholar
• ADVANCED BIOTHERAPY CONCEPTS, INC: Company announces collaboration with GroupMed CRO for the funding and management of clinical trials in Mexico for rheumatoid arthritis. Press Release. (June 5, 1997).
   Google Scholar
• Seventh Annual IBC International Conference On An-tibody Engineering: New Technology, Application & Commercialization. IDdb Meeting Report (1996). Co-ronado, (December 2–4, 1996).
   Google Scholar
• SALFELD J. KAYMAKCALAN Z, ALLEN D et al.: Develop-ment of a fully human anti-TNF antibody by phage dis-play technology. J. Interf Cyto. Res. (1998) 18:A125.
   Google Scholar
• REINHART K, WIEGAND-LOHNERT C, GRIMMINGER F et al.: Assessment of the safety and efficacy of the mono-clonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Grit. Care Med. (1996) 24(5):733–742.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Treatment of rheumatoid arthritis with chimeric monoclonal anti-bodies to tumour necrosis factor-alpha. Arthritis Rheum. (1993) 36(12):1681–1690.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lan-cet (1994) 344(8930):1125–1127.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal an-tibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344 (89301105–1110.
   Google Scholar
• VAN DULLEMEN HM, HOMMES DW, MEENAN J et al:Complete remissions of steroid-refractory Crohn's disease after administration of monoclonal anti-TNF antibody cA2. Gastroenterology (1994) 106(4A) 1054
   Google Scholar
• VAN DULLEMENHM, VAN DEVENTERSJ, HOMMES DW et al Treatment of Crohn's disease with anti-tumor ne-crosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109(1):129–135.
   PubMed Web of Science ®Google Scholar
• CENTOCOR INC: Centocor announces results from studies of Crohn's disease therapy. Press Release (May 13, 1997).
   Google Scholar
• KNIGHT DM, TRINH H, LE J et al.: Construction and ini-tial characterization of a mouse-human chimeric anti-TNF antibody. Mot. Immunot (1993) 30(16):1443–1453.
   PubMed Web of Science ®Google Scholar
• SIEGEL SA, SHEALY DJ, NAKADA MT et al.: The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine (1995) 7(1):15–25.
   PubMed Web of Science ®Google Scholar
• GALLO MA, DERITA R, MACE KF et al.: Treatment ofpolyarthritis with chimeric A2 antibody in transgenic mice expressing human tumor necrosis factor alpha. Int. Congr. Inflamm. Res. Assoc. (October 27–31, 1996) Her-shey, Penn., USA. Abstract W24.
   Google Scholar
• GALLO MA, DERITA R, MACE KF et al.: Treatment of polyarthritis with chimeric A2 antibody in transgenic mice expressing human tumor necrosis factor alpha. mt. Congr. Inflamm. Res. Assoc. (October 27–31, 1996) Her-shey, Penn., USA. Abstract W24.
   Google Scholar
• SCALLON BJ, MOORE MA, TRINH H: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune ef-fector functions. Cytokine (1995) 7(3)251–259.
   Google Scholar
• WALKER RE, SPOONER KM, KELLY G et al.: Inhibition of immunoreactive tumor necrosis factor-alpha by a chi-meric antibody in patients infected with human im-munodeficiency virus Type 1. Infect. Dis. (1996) 174 (1)63–68.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Randomised double-blind comparison of chimeric monoclonal an-tibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344(89301105–1110.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthri-tis. Lancet (1994) 344(89301125–1127.
   Google Scholar
• FELDMAN M: Anti-TNF alpha therapy in rheumatoid ar-thritis rationale, results and mode of action. All CR (Oc-tober 14–18, 1995). Abstract 12.
   Google Scholar
• Centocor's CenTNE to start Phase III in Crohns/Rheu-matoid Arthritis. SCRIP (1997) 2216:26.
   Google Scholar
• VAN DULLEMEN HM, HOMMES DW, MEENAN J: Com-plete remissions of steroid-refractory Crohn's disease after administration of monoclonal anti-TNF antibody cA2. Gastroenterology (1994) 106(4A):1054.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Randomiseddouble-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344 (89301105–1110.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lan-cet (1994) 344 (8930) :1125–1127.
   PubMed Web of Science ®Google Scholar
• AMGEN, INC: Amgen updates financial community on clinical progress and new research programs. Press Re-lease (March 4, 1997).
   Google Scholar
• AMGEN, INC: Amgen 1996 Annual Report. Annual Re-port (1996).
   Google Scholar
• Infergen - Amgen's next launch? SCRIP (1996) 2124:11.
   Google Scholar
• AMGEN, INC: Amgen announces start of TNF-bp clinical trial in rheumatoid arthritis. Press Release (April 15, 1996).
   Google Scholar
• IMMUNEX CORP: FORM 10-K ( December 31, 1993).
   Google Scholar
• MOHLER KM, TORRANCE DS, SMITH CA, GOODWIN RG: Soluble Tumor Necrosis Factor (TNF) Receptors are ef-fective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunot (1993) 151:1548–1561.
   Google Scholar
• JACOBS CA, BECKMAN MP, MOHLER K et al.: Pharma-cokinetic Parameters and Biodistribution of Soluble Cytokine Receptors. Int. Rev. Exp. Pathol. (1993) 34B:123–135.
   Google Scholar
• EVANS TJ, MOYES D, CARPENTER A et al.: Protective Ef-fect of 55- but not 75 kD Soluble Tumor Necrosis Factor receptor-Immunoglobulin G Fusion Proteins in an Animal Model of Gram-negative Sepsis. J. Exp. Med. (1994) 180:2173–2179.
   PubMed Web of Science ®Google Scholar
• DENIS M, GUOJIAN L, WIDMER M, CANTIN A: A mouse model of lung injury induced by microbial products: implication of tumor necrosis factor. Am. J. Respir. Mot. Biol. (1994) 10(6):658–664.
   PubMed Web of Science ®Google Scholar
• WOOLEY PH, DUTCHER J, WIDMER MB, GILLIS S: Influ-ence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. (1993) 151(11) :6602–6607.
   PubMed Web of Science ®Google Scholar
• IMMUNEX CORP: Immunex announces results of piv-otal trial for Enbrel in rheumatoid arthritis, confirm-ing effectiveness. Press Release (September 11, 1997).
   Google Scholar
• IMMUNEX CORP: Immunex arthritis drug shown safe with additional data. Press Release (June 11, 1997).
   Google Scholar
• IMMUNEX CORP: Enbrel (TM) study published today shows RA patients' symptoms improve. Press Release (July 18, 1997).
   Google Scholar
• MARGOLIES G, HECK LW, SAWAY A: Recombinant solu-ble tumor necrosis factor receptor (p80) fusion pro-tein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. (1996) 23:1849–1855.
   PubMed Web of Science ®Google Scholar
• NAM MH, REDA D, BOUJOUKOS AJ, AGOSTI J, SUFFRE-DINI AF: Recombinant human dimeric tumor necrosis © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(11) factor TNF receptor TNFR fc safety and pharmacoki-netics in human volunteers. Clin. Res. (1993) 41 (2):249A.
   Google Scholar
• FISHER CJJR, AGOSTI JM, OPAL SM et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. NewEngl. J. Med. (1996) 334(26):1697–1702.
   Google Scholar
• SUFFREDINI AF, REDA D, BANKS SM et al.: Effects of re-combinant dimeric TNF receptor on human inflamma-tory responses following intravenous endotoxin administration. J. Immunol. (1995) 155(10)5038–5045.
   Google Scholar
• IMMUNEX CORP: Immunex and American Home Prod-ucts' Pharmaceutical Division, Wyeth-Ayerst, to pro-mote ENBREL in North America/ Immunex research advance aimed at major Pharmaceutical markets. Press Release (September 25, 1997).
   Google Scholar
• Roche parathyroid hormone osteoporosis research has candidate in Phase II. FDC Reports Pink Sheet (1996) 58(44): T&G-17-T&G–18.
   Google Scholar
• WILLIAMS RO, GHRAYEB J, FELDMANN M, MAINI RN: Suc-cessful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology (1995) 84(3):433–439.
   PubMed Web of Science ®Google Scholar
• LESSLAUER W, TABUCHI H, GENTZ R: Recombinant soluble tumor necrosis factor receptor proteins pro-tect mice from lipopolysaccharide-induced lethality. Eur.J. Immunol. (1991) 21(10:2883–2886.
   PubMedGoogle Scholar
• VAN ZEE KJ, MOLDAWER LL, OLDENBURG HAS et al: Pro-tection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45–2081.1 Immunol. (1996) 156(6):2221–2230.
   Google Scholar
• GOODSALL AL, LEMCKERT FA, SCALLON BJ: Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune en-cephalomyelitis. Proc. Natl. Acad. Sci. USA (1995) 24:11066–11070.
   Google Scholar
• LIU X, MASHOUR GA, KURTZ A: Recent developments in the treatment of encephalomyelitis. Exp. Opin. Ther. Pat. (1996) 6(5):457–470.
   Web of Science ®Google Scholar
• TNF neutralization does not cause auto-antibody changes: The experience with 521 patients enrolled into IV RO 45–2081 trials. (ACR Meeting 1997).
   Google Scholar
• 30 months of treatment with a TNEcc receptor-fusion protein (TNER55-IgGl, RO 45–2081) in patients with se-vere refractory RA. (ACR meeting 1997).
   Google Scholar
• HASLER F, VAN DEPUTTEL, BAUDIN M: Chronic TNF neutralization (up to 1 year) by Lenercept (TNE-R55-IgGl, Ro 45–2081) in patients with rheumatoid arthri-tis: results of an open-label extension of double-blind single dose Phase I study. Arthritis Rheum. (1996) 39(9). (Suppl. S243).
   Google Scholar
• HASLER F, VAN DEPUTTEL, DUMONT E et al.: Safety and efficacy of TNF neutralization by Lenercept (TNE-R55-IgGl, Ro 45–2081) in patients with rheumatoid arthri-tis exposed to a single dose. Arthritis Rheum. (1996) 39(9). (Suppl. S243).
   Google Scholar
• BUTLER DM, SCALLON B, MEAGER A: TNF receptor fu-sion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine (1994) 6 (6) :616–623.
   PubMed Web of Science ®Google Scholar
• GLAUSER M, ABRAHAM E, LATERRE PF: Ro 45–2081 (TNEr-lgG1) in the treatment of severe sepsis and sep-tic shock: correlates of treatment, baseline cytokine levels and outcome. ICAAC (Sep 17–20 1996) 36. Abstract G10.
   Google Scholar
• HASLER F, VAN DEPUTTEL, DUMONT E et al.: Safety and efficacy of TNF neutralization by Lenercept (TNE-R55-IgGl, Ro 45–2081) in patients with rheumatoid arthri-tis exposed to a single dose. Arthritis Rheum. (1996) 39:9. (Suppl. S243).
   Google Scholar
• SANDER O, RAU R, VAN RIELP: Neutralization of TNF by Lenercept (TNF-R55-IgG, Ro 45–2081) in patients with rheumatoid arthritis treated for 3 months: Results of a European phase II trial. Arthritis Rheum. (1996) 39(9). (Suppl. S242).
   Google Scholar
• RAU R, SANDER O, SCHATTENKIRCHNER M et al.: Monthly vs. bimonthly dosing of Lenercept (TNE-R55-IgGl, Ro 45–2081) in patients with rheumatoid arthri-tis treated for 3 months: Results of a double-blind con-trolled Phase II trial. Arthritis Rheum. (1996) 39 (9) Suppl. S243.
   Google Scholar
• FURST D, WEISMAN M, PAULUS H: Neutralization of TNF by Lenercept (TNF-R55-IgGl, Ro 45–2081) in patients with rheumatoid arthritis treated for 3 months: Re-sults of an US phase II trial. Arthritis Rheum. (1996) 39(9). (Suppl. S243).
   Google Scholar
• ROSS SE, WILLIAMS RO, MASON LJ et al: Suppression of TNEcc expression, inhibition of Thl activity, and ame-lioration of collagen-induced arthritis by rolipram. J. Immunol. (1997) 159:6253–6259.
   PubMed Web of Science ®Google Scholar
• KUNKEL SL, SPENGLER M, MAY MA et al.: Prostaglandin E2 regulates macrophage-derived tumor necrosis fac-tor gene expression. J. Biol. Chem. (1988) 263:5380–5484.
   PubMed Web of Science ®Google Scholar
• ZELLER E, STIEF HJ, PFLUG B, SASTRE Y, HERNANDEZ M: Results of a Phase II study of the antidepressant effect of rolipram. Pharmacopsychiatly (1988) 17:188–190.
   Google Scholar
• KIELY PDW, GILLESPIE KM, OLIVEIRA DBG: Pentoxifyl-line inhibits TNF alpha mRNA production and protects against experimental arthritis. Inflamm. Res. (1995) 44. (Suppl 3). W16/04.
   Google Scholar
• MOLE L, MARGOLIS D, GHOTBI L, HOLODNIY M: The use of pentoxifylline alone in HIV-infected patients. J. Ac-quired Immune Defic. Syndr. (1994) 7(5):519–521.
   PubMed Web of Science ®Google Scholar
• ANDRULIS: Thalidomide studied against multiple scle-rosis: Andrulis Pharmaceuticals and UCLA commence trial. Press Release (September 27, 1995).
   Google Scholar
• ANDRULIS: Andrulis Pharmaceuticals announces col-laboration, patent using thalidomide agains Alzheim-ers. Press Release (August 7, 1995).
   Google Scholar
• ANDRULIS: Thalidomide Effectively Heals Aphthous Ul-cers in AIDS Patients, NIH Study Shows. Press Release (May 22, 1997).
   Google Scholar
• JACOBSON JM, GREENSPAN JS, SPRITZLER J et al.: Tha- lidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infec-tion. New Engl. J. Med. (1997) 336(20:1487–1493.
   PubMedGoogle Scholar
• Thalidomide. Clin. Trials Monitor (1995) 4(12):P12.
   Google Scholar
• Clinical Trial Updates - Company-sponsored studies - Phase I - Andrulis Pharmaceuticals: Thalidomide Re-search. FDC Reports Pink Sheet (1995) 45: (Suppl 37).
   Google Scholar
• CELGENE CORP: Thalidomide recommended for FDA approval by US FDA advisory committee. Press Release (September 5, 1997).
   Google Scholar
• CELGENE CORP: Celgene receives FDA approvable let-ter for thalidomide; first-line treatment for complica-tions of surgery. Press Release (September 22, 1997).
   Google Scholar
• ICOS CORP: Celgene files ND application for thalido-mide to treat Behcet's disease and complex aphthosis. Press Release (September 26, 1997).
   Google Scholar
• Celgene tests Synovir in rheumatoid arthritis. SCRIP (1995) 20:26–27.
   Google Scholar
• CELGENE CORP: American Chemical Society reports on new category of anti-inflammatory drugs derived from thalidomide. Press Release (August 19, 1996).
   Google Scholar
• CELGENE CORP: New thalidomide analogs promise more potent, potentially safer drugs for controlling in-flammatory disease. Press Release (July 25, 1996).
   Google Scholar
• MULLER GW, CORRAL LG, SHIRE MG et al.: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem. (1996) 39(17)3238–3240.
   Google Scholar
• Celgene Corporation. Annual Report (October 1994).
   Google Scholar
• CELGENE CORP: Celgene Corporation launches clinical trials for new class of TNF-alpha inhibitors. Press Re-lease (September 29, 1997).
   Google Scholar
• Celgene's novel thalidomide analogues. SCRIP (1996) 15:2159–2160.
   Google Scholar
• Conquering airway inflammation in the 21st cen-tury.15–17 September 1997, National Heart and Lung Institute, London, UK. IDdb Meeting Report (1997).
   Google Scholar
• WILHELM RS, AXT S, ALVAREZ R, FONG A: N-3-Aryl xan-thines; potent and selective inhibitors of phosphodi- esterase type IV (PDEACS (1995) 209th Anaheim.Abstract 173.
   Google Scholar
• LOE BE, WILHELM RS, ALVAREZ R, FONG A: Synthesis and biological evaluation of pyrido [2,3-d] pyridazin-5-ones as type IV phosphodiesterase inhibitors. ACS (1995) 209th Anaheim. Abstract 186.
   Google Scholar
• WILHELM RS, FATHEREE P, ALVAREZ R, FONG A: 8-Aryl Quinolones as Potent and Selective Type IV Phos-phodiesterase Inhibitors. ACS (1995) 209th Anaheim. Ab-stract 187.
   Google Scholar
• XlVth International Symposium on Medicinal Chemis-try (Part 0, Maastricht, The Netherlands, September 8–12, 1996. IDdb Meeting Report (1996).
   Google Scholar
• MOLNAR KIMBER-K-L, YONNO L, RHOAD A, WEICHMANB-M, HEASLIP R-J: Inhibition of tumor necrosis factor alpha secretion from endotoxin stimulated human monocytes by WAY-PDA-641 and rolipram. J. Immunol (1993) 150:(8 PART 2):295A.
   Google Scholar
• HEASLIP R J, LOMBARDO LJ, GOLANKIEWICZ JM et al.: Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. BMJ Pharmacol. Exp. Ther. (1994) 268(2):888–896.
   PubMed Web of Science ®Google Scholar
• HEASLIP RJ, EVANS DY, SICKELS BD: Pulmonary selectiv-ity of WAY-PDA-641 and reference PDE-IV inhibitors in the dog. Faseb J. (1994) 8 (4-5) :A371.
   PubMed Web of Science ®Google Scholar
• Celltech drops asthma drug. SCRIP (1996) 210:114.
   Google Scholar
• MCGEEHAN GM, BECHERER JD, BLAST RC Jr et al: Regula-tion of tumor necrosis factor-? processing by a metal-loproteinase inhibitor. Nature (1994) 370:558–561.
   PubMed Web of Science ®Google Scholar
• CONWAY JG, WAKEFIELD JA, BROWN RH et al.: Inhibi-tion of adjuvant arthritis in rats by a neutral metallo-protease inhibitor. J. Exp. Med. (1995) 182:449–457.
   PubMed Web of Science ®Google Scholar
• BLACK RA, BIRD TA, MOHLER KM: Agents that block TNF-asynthesis or activity. Annual Reports in Medicinal Chemistry, Section V-Topics in Biology, Chap. 24:241–250.
   Google Scholar
• BAXTER AD, BIRD J, BHOGAL R: A novel series of matrixmetalloproteinase inhibitors for the treatment of in-flammatory disorders. Biorg. Med. Chem. Lett. (1997) 7:897–902.
   Web of Science ®Google Scholar
• DENIS LJ, VERWEIJ J: Matrix metalloproteinase inhibi-tors: present achievements and future prospects. In-vest. New Drugs (1997) 15:175–185.
   PubMed Web of Science ®Google Scholar
• WOJTOWICZ-PRAGA SM, DICKSON RB, HAWKINS MJ: Matrix metalloproteinase inhibitors. Invest. New Drugs (1997) 15:61–75.
   PubMed Web of Science ®Google Scholar